主页 > 医学讨论 >
【medical-news】度洛西汀之于抑郁症：疗效与病情
aDepartment of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee bLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
Clinicians need to know whether duloxetine is effective in patients across a broad range of depressive symptoms and depression severity. Data were pooled from nine randomized, double-blind, placebo-controlled studies in major depressive disorder (total N=2227) comparing duloxetine (40-120 mg/day) with placebo for 8-9 weeks. Patients were retrospectively stratified by baseline score on the HAMD17 into mild (</=19; n=682), moderate (n=1099), or severe (>/=25; n=446) groups. Duloxetine produced significantly greater baseline-to-endpoint mean change than placebo in HAMD17 total score, Maier and retardation subscales, and the Clinical Global Impressions-Severity of Illness scale in all three cohorts. Significant improvement was seen in HAMD17 items 1 (depressed mood), 3 (suicide), 7 (work and activities), and 10 (psychic anxiety) regardless of severity. The HAMD17 anxiety subscale and items 13 (somatic symptoms-general) and 15 (hypochondriasis) showed significant improvement only in moderately and severely ill patients. Significant improvement in the HAMD17 Maier subscale was seen in all groups by week 1. In all three groups, placebo was significantly superior to duloxetine at early visits on HAMD17 item 12 (somatic symptoms-GI). Mildly and severely ill patients exhibited significant reduction in visual analog scale overall pain severity at the study endpoint. The studies contained fewer patients with very mild or very severe illness, limiting our ability to draw conclusions in these patient populations. Duloxetine demonstrated superior efficacy in the treatment of major depressive disorder, when compared with placebo, regardless of the baseline severity of depressive symptoms, although effect sizes were largest in the most severely depressed patients.
http://www.docguide.com/news/content.nsf/PaperFrameSet?OpenForm&newsid=852571020057CCF68525736D003ECF73&topabstract=1&u=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17917553 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 请专业战友指教！
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
度洛西汀之于抑郁症：疗效与病情无关
aDepartment of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee bLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
田纳西州Nashville, Vanderbilt大学医学院精神病学部；美国印第安纳州Indianapolis礼来公司礼来实验室
Clinicians need to know whether duloxetine is effective in patients across a broad range of depressive symptoms and depression severity.
临床医生需要知道，度洛西汀是否对不同抑郁症状及严重程度不同的患者有效。
Data were pooled from nine randomized, double-blind, placebo-controlled studies in major depressive disorder (total N=2227) comparing duloxetine (40-120 mg/day) with placebo for 8-9 weeks.
数据来自于九项针对严重抑郁症患者（总数N=2227）的随机双盲安慰剂对照试验，进行8-9周试验比较度洛西汀(40-120 mg/day)和安慰剂的疗效。
Patients were retrospectively stratified by baseline score on the HAMD17 into mild (</=19; n=682), moderate (n=1099), or severe (>/=25; n=446) groups.
根据患者开始的HAMD17量表评分对患者进行分组，分成轻度(</=19; n=682)，中度(n=1099)和重度(>/=25; n=446)三组。
Duloxetine produced significantly greater baseline-to-endpoint mean change than placebo in HAMD17 total score, Maier and retardation subscales, and the Clinical Global Impressions-Severity of Illness scale in all three cohorts.
从开始到试验结束，三组的HAMD17总分、焦虑和迟缓量表评分及临床疗效总评定量表评分中，度洛西汀组的平均改善作用都明显高于安慰剂组。
Significant improvement was seen in HAMD17 items 1 (depressed mood), 3 (suicide), 7 (work and activities), and 10 (psychic anxiety) regardless of severity. The HAMD17 anxiety subscale and items 13 (somatic symptoms-general) and 15 (hypochondriasis) showed significant improvement only in moderately and severely ill patients.
不管患者开始病情如何，HAMD17量表中的第一项（抑郁情绪）、第三项（自杀）、第七项（工作和兴趣）及第十项（精神性焦虑）都有显著改善。HAMD17焦虑量表和第13项（全身症状）及第15项（疑病）仅在中重度患者中出现显著改善。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-17 18:05
医学,生命科学网